ArticleResearch square2023
Human ILC1s target leukemia stem cells and control development of AML.
Michael Caligiuri, Zhenlong Li, Rui Ma, Hejun Tang, Jianying Zhang, Guido Marcucci, Jianhua Yu
Open access · greenAbstract readPreprint
In one paragraphArticle in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors at 1 institution in 1 country.
Zhenlong LiCity of Hope National Medical Center.
Rui MaCity of Hope National Medical Center.
Hejun TangCity of Hope National Medical Center.
Jianying ZhangCity of Hope National Medical Center.
City Of Hope National Medical Center · US
Funding
The Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI Xiaokui Mo · 2013 to 2026
$26.0MHuman natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3MTasquinimod as an adjunct to immunotherapies administered peri-operativelyU19CA264512 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Behnam Badie, Jana Portnow · 2021 to 2026
$6.0MTargeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaR01CA265095 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BUDDE, LIHUA ELIZABETH, CALIGIURI, MICHAEL A · 2021 to 2025
$2.4MCharacterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK CellsR01CA247550 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2020 to 2024
$2.2MElucidate and Modulate Cell Signaling in NK Cells for Glioma TreatmentR01AI129582 · NIAID · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2017 to 2021
$2.1MOvercoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9MPhase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint InhibitorsR01CA266457 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALONA, MIGUEL A, YU, JIANHUA · 2022 to 2025
$1.8MscFvPD1-FLT3 CAR T Cells for the Treatment of Relapsed Acute Myeloid LeukemiaR21CA223400 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2019 to 2020
$414kNCI NIH HHS P01 CA163205NCI NIH HHS R01 CA247550NCI NIH HHS R01 CA265095NCI NIH HHS R01 CA266457NCI NIH HHS R21 CA223400NCI NIH HHS R35 CA210087NCI NIH HHS U19 CA264512NIAID NIH HHS R01 AI129582NINDS NIH HHS R01 NS106170
6 · The paper itselfAbstract
Innate lymphocytes can mediate cancer immunosurveillance and protect against disease. We have demonstrated that mouse type I innate lymphoid cells (ILC1s) can contribute to controlling the growth of acute myeloid leukemia (AML). However, the functional roles of human ILC1s in AML remain largely undefined. Here, we found that the ILC1s in patients with AML are impaired while a high expression of the ILC1 gene signature is associated with better overall survival in AML. By directly interacting with leukemia stem cells (LSCs), human ILC1s can eliminate LSCs via production of IFNγ and block LSC differentiation into M2 macrophage-like, leukemia-supporting cells through TNF. Collectively, these effects converge to limit leukemogenesis
Identifiers
PMID36711868
PMCPMC9882609
OpenAlexW4315432654
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390